<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231208060297N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-01-28</date_registration>
      <primary_sponsor>The university of Lorestan</primary_sponsor>
      <public_title>The effects of resistance training, detraining, and retraining on the serum levels of FGF6 and Myod in middle-aged men and women</public_title>
      <acronym></acronym>
      <scientific_title>The effects of 12 weeks of resistance training,  24 weeks of detraining, and 24 weeks of retraining on the serum levels of FGF6 and Myod in middle-aged men and women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74953</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Blinding description: In the current study, only the group that takes blood samples from the subjects and extracts the desired factors in the laboratory, as well as the group that analyzes the extracted data, are kept blind to the study.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Examining changes in serum levels of FGF6 and Myod after 12 weeks of resistance training, 24 weeks of non-training and 12 weeks of retraining in middle-aged people.</hc_freetext>
      <i_freetext>Intervention group: Subjects under the supervision of an experienced trainer participated in a strength training program of three sessions per week for 12 weeks. Each training session consisted of a dynamic warm-up, cool-down phase, and a strength program that lasted approximately 60 minutes. This protocol includes upper body exercises (shoulder press, wide-grip lat pulldown, crunches, chest press, barbell Croul) and lower body (leg press on a 45-degree table, leg press on a 45-degree table, front leg of the machine) with sets and repetitions with progress It was from 2 to 3 and respectively and from 15 to 8 repetitions. The training load intensity was gradually increased from 65% of 1RM to 80% of 1RM. Every four weeks, the 1RM test was repeated for the chest and leg press movements to determine the maximum weight that could be correctly performed in one repetition to evaluate strength changes. After the training period, the subjects are asked to resume their normal physical activities as before the start of the study and not participate in strength training for 24 weeks. A 24-week no-training period is followed by a 12-week retraining phase, using the same resistance training program with starting loads of each exercise appropriate to the physical condition. 48 hours before and after the intervention, blood will be taken from all the subjects and the plasma levels of FGF-6 and MyoD will be checked using the desired kits and by ELISA method..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After the publication of scientific work, all information can be shared after identifying people

When:
Looking forward to printing the results

To whom:
People working in academic institutions and other community members will have access

Conditions:
Having a research background in the field of the current study and practical use in the field of health for middle-aged and elderly people in society

Where to obtain:
To receive data, write to the email address: mohsen.yaqoubi@gmail.com

How to obtain:
Request information only in the form of e-mail and information will be sent as soon as possible

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>MohsenYaghoubi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 3, Vista Building, Gulshan Alley, Mirzai Shirazi Boulevard, Sobhani</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3815963747</zip>
        <telephone>+98 86 3276 0257</telephone>
        <email>mohsen.yaqoubi@gmail.com</email>
        <affiliation>The university of Lorestan</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Masoud Rahmati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Central Organization of Lorestan University - Kilometer 5 of Tehran Road - Khoram Abad City - Lorestan Province</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6815144316</zip>
        <telephone>+98 66 3312 0097</telephone>
        <email>masoud2_rahmati@yahoo.com</email>
        <affiliation>The university of Lorestan</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>having physical health
Willingness to participate in research
Failure to perform any type of endurance or strength training in the 12 months prior to the study</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>59 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having any type of chronic disease
Musculoskeletal injury and joint disorders
Use of any type of medicine or supplement</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Subjects under the supervision of an experienced trainer participated in a strength training program of three sessions per week for 12 weeks. Each training session consisted of a dynamic warm-up, cool-down phase, and a strength program that lasted approximately 60 minutes. This protocol includes upper body exercises (shoulder press, wide-grip lat pulldown, crunches, chest press, barbell Croul) and lower body (leg press on a 45-degree table, leg press on a 45-degree table, front leg of the machine) with sets and repetitions with progress It was from 2 to 3 and respectively and from 15 to 8 repetitions. The training load intensity was gradually increased from 65% of 1RM to 80% of 1RM. Every four weeks, the 1RM test was repeated for the chest and leg press movements to determine the maximum weight that could be correctly performed in one repetition to evaluate strength changes. After the training period, the subjects are asked to resume their normal physical activities as before the start of the study and not participate in strength training for 24 weeks. A 24-week no-training period is followed by a 12-week retraining phase, using the same resistance training program with starting loads of each exercise appropriate to the physical condition. 48 hours before and after the intervention, blood will be taken from all the subjects and the plasma levels of FGF-6 and MyoD will be checked using the desired kits and by ELISA method.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Increase in serum concentration of FGF6 after 12 weeks of resistance training in middle-aged women and men. Timepoint: At the beginning of the study, 12 weeks after the first intervention, 24 weeks after the second intervention, and 12 weeks after the third intervention. Method of measurement: ELISA kit.</prim_outcome>
      <prim_outcome>Increase in serum concentration of Myod after 12 weeks of resistance training in middle-aged women and men. Timepoint: At the beginning of the study, 12 weeks after the first intervention, 24 weeks after the second intervention, and 12 weeks after the third intervention. Method of measurement: ELISA kit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The university of Lorestan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-11-20</approval_date>
        <contact_name>The Ethics Committee of Sports Sciences Research Institute (SSRI)</contact_name>
        <contact_address>Unit 3, Vista Building, Gulshan Alley, Mirzai Shirazi Boulevard, Sobhani Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
